Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Open public hearings

This article was originally published in The Tan Sheet

Executive Summary

Individuals who wish to present during open public hearings at advisory committee meetings are not required to disclose financial ties, FDA says in a draft guidance published in the Federal Register Feb. 15. Although disclosure is encouraged, panelists should not ask further questions about a potential link, but may ask for further details on scientific content, the draft guidance adds...

You may also be interested in...



Open Public Hearing Speakers Should Disclose Financial Conflict – Comments

FDA should permit advisory committee members and voting consultants to question open public hearing speakers about their potential conflicts of interest during advisory committee meetings, according to the consumer advocacy group Public Citizen

Pfizer Upjohn’s Ray On Changing The Grave Trajectory Of NCDs

Pfizer Upjohn’s Global President of R&D and Medical, Amrit Ray, talks in a wide-ranging interview about the need for tailored interventions to address the growing burden of non-communicable diseases and efforts around harnessing real world data. He also underscores the importance of investing in primary care and a primary health workforce against the backdrop of outbreaks such as coronavirus.

QUOTED. 24 February 2020. Daniel Taddeo.

Political tensions between Switzerland and the EU have led to concerns about the future status of the only Swiss medtech notified body, SQS. Here’s what SQS board member Daniel Taddeo said about the situation.

Topics

UsernamePublicRestriction

Register

PS097878

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel